Table 1.
Baseline characteristics of the study population (N = 398 patients).
| Characteristics | All Patients (N = 398) |
Frontline IMA Patients (N = 291) |
Frontline 2–3G TKI Patients (N = 107) |
p-Value |
|---|---|---|---|---|
| Median age at diagnosis, years (range) | 61.6 (18.6–90.2) | 63.9 (18.6–90.2) | 54.0 (22.7–82.9) | <0.001 |
| ≥70, n pts (%) <45, n pts (%) |
106 (26.6) 77 (19.3) |
94 (32.3) 40 (13.7) |
12 (11.2) 37 (34.5) |
<0.001 <0.001 |
| Gender, female, n pts (%) | 168 (42.2) | 123 (42.2) | 45 (42.0) | 0.532 |
| Sokal risk score, n pts (%) | 0.022 | |||
| Low | 112 (28.1) | 81 (27.8) | 31 (28.9) | |
| Intermediate | 193 (49.7) | 149 (51.2) | 44 (41.2) | |
| High | 76 (19.0) | 46 (15.8) | 30 (28.0) | |
| Unknown | 17 (4.2) | 15 (5.1) | 2 (1.8) | |
| ELTS risk score, n pts (%) | 0.054 | |||
| Low | 199 (50.0) | 138 (47.7) | 61 (56.0) | |
| Intermediate | 122 (30.6) | 98 (33.3) | 24 (23.3) | |
| High | 53 (13.3) | 35 (12.0) | 18 (16.8) | |
| Unknown | 24 (6.0) | 20 (6.8) | 4 (3.7) | |
| Non-M BCR-ABL1 transcript, n pts | 3 | 3 | 0 | 0.373 |
| ACA at diagnosis, n pts (%) | 30 (7.5) | 22 (7.5) | 8 (7.4) | 0.584 |
| ACA major route at diagnosis, n pts (%) | 12 (3.0) | 8 (2.7) | 4 (3.7) | 0.410 |
| First-line TKI type and initial daily dose, n pts (%) | ||||
| Imatinib 400 | 276 (69.3) | 276 (94.8) | NA | |
| Imatinib > 400 | 7 (1.7) | 7 (2.4) | NA | |
| Imatinib < 400 | 8 (2.0) | 8 (2.7) | NA | |
| Nilotinib 600 | 69 (17.3) | NA | 69 (64.4) | |
| Nilotinib 800 | 8 (2.0) | NA | 8 (7.4) | |
| Dasatinib 100 | 26 (6.5) | NA | 26 (24.3) | |
| Bosutinib 500 | 2 (0.5) | NA | 2 (1.8) | |
| Ponatinib 45 | 2 (0.5) | NA | 2 (1.8) |
Abbreviations: IMA, Imatinib; TKI, Tyrosine Kinase Inhibitor; 2–3G TKI, tyrosine kinase inhibitor of second and third generation; pts, patients; ACA, Additional Cytogenetic Abnormalities; NA, Not Applicable.